Cancer name Lymphoma
Cancer Type DLBC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment SB415286
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature LAMP1
Official Symbol LAMP1
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Flow cytometry of T-cells isolated from the spleens, draining lymph nodes and TILs demonstrated lower expression levels of PD-1. This was confirmed with PCR demonstrating a reduction in Pdcd1 and an increase in Tbx21.
PMID 29055015
Title Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy